Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05631873 · ClinicalTrials.gov registry record · NA
Colonoscopy Screening: Setting Epic Follow-up Times
A NA study of Colorectal Cancer and Concordance Between Colonoscopy Follow up Interval Noted in Patient Letters vs. Electronic Health Record Chart, sponsored by Massachusetts General Hospital.
- Completed
- Registry status
- NA
- Development phase
- 43
- Enrollment target
- 1
- Study location
NCT05631873: Completed NA study of Colorectal Cancer and Concordance Between Colonoscopy Follow up Interval Noted in Patient Letters vs. Electronic Health Record Chart, sponsored by Massachusetts General Hospital.
NCT05631873 is a NA study of Colorectal Cancer and Concordance Between Colonoscopy Follow up Interval Noted in Patient Letters vs. Electronic Health Record Chart that has completed, run by Massachusetts General Hospital. The registered enrollment target is 43 participants, below the 1,545-participant average among 381 other Colorectal Cancer trials with a reported enrollment target (97% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05631873, a NA study of Colorectal Cancer and Concordance Between Colonoscopy Follow up Interval Noted in Patient Letters vs. Electronic Health Record Chart, has completed, sponsored by Massachusetts General Hospital.
- COMPLETED
- Registry status
- NA
- Development phase
- 43 participants
- Enrollment target
- 1
- Study location
Study Summary
Screening for colorectal cancer can reduce its incidence and mortality but is a complex, error-prone process. The value of screening with colonoscopy is in removing pre-cancerous polyps that increase one's risk for future cancer. Abnormal results are common, and failure to receive recommended follow-up undermines the benefits of screening, violates the trust that patients place in their providers, and increases medicolegal risk. This proposal seeks to ensure that the foundation of safety systems, the recommendations for the follow-up interval reflect current guideline recommendations and are accurately updated. Specifically, the investigators will implement and evaluate in a randomized trial a new colonoscopy result letter as part of usual care that automatically updates the recommended follow-up interval in the patient's health record compared to the current result letter format.
Primary Outcome
Provider level: any use (yes/no) of the structured result template letter among all randomized providers
Conditions Studied
Interventions
- OTHER Assistance with implementing Epic Smartlist
Study Locations (1)
Massachusetts
- Massachusetts General Hospital - Boston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 43 participants |
| Start Date | 2022-11-18 |
| Est. Completion | 2024-03-11 |
| Phase | NA |
What the finished NCT05631873 record still lists
NCT05631873 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 43 participants, a relatively small participant target, below the 1,545-participant average among 381 other Colorectal Cancer trials with a reported enrollment target (97% lower).
The record links to 2 conditions, with Colorectal Cancer appearing as the primary indexed condition, and to 1 intervention - of which Assistance with implementing Epic Smartlist is the first listed.
NCT05631873 reports a single indexed study location in Massachusetts.
Frequently Asked Questions
What is clinical trial NCT05631873 about?
NCT05631873 is a clinical study titled "Colonoscopy Screening: Setting Epic Follow-up Times". Screening for colorectal cancer can reduce its incidence and mortality but is a complex, error-prone process. The value of screening with colonoscopy is in removing pre-cancerous polyps that increase one's risk for future cancer. Abnormal results are common, and failure to receive recommended follow...
What is the current status of trial NCT05631873?
This trial is currently completed. It is a NA study. The enrollment target is 43 participants. The study started on 2022-11-18. Estimated completion is 2024-03-11.
What conditions does trial NCT05631873 study?
This clinical trial studies the following conditions: Colorectal Cancer, Concordance Between Colonoscopy Follow up Interval Noted in Patient Letters vs. Electronic Health Record Chart.
What interventions are being tested in trial NCT05631873?
The interventions under investigation include: Assistance with implementing Epic Smartlist (OTHER).
Who is sponsoring clinical trial NCT05631873?
This trial is sponsored by Massachusetts General Hospital, which has 2,032 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05631873 being conducted?
This trial has 1 study location across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Colorectal Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05631873's enrollment target sits among peer trials
43 291st of 381 higher than 90 of 381 other Colorectal Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Colorectal Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Cross-sectional Partnership to Improve Prevention and Health Equity Among African Americans
RECRUITING · NA
-
Precise Oncology Interventions in Nutrition and Training (OnPoint)
RECRUITING · NA
-
Resistance Exercise and Creatine in Colorectal Cancer
RECRUITING · NA
-
Optimal Perioperative Pain Control in Minimally Invasive Abdominal Cancer Surgery
RECRUITING · NA
-
Ultrasound and Photoacoustic Imaging for Enhanced Differential Diagnosis of Rectal Cancer
RECRUITING · NA
-
Mediterranean Diet and Weight Loss: Targeting the Bile Acid/Gut Microbiome Axis to Reduce Colorectal Cancer
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03726359 · 43 participants · Phase 1
Phase I Study of Fractionated Stereotactic Radiation Therapy
- NCT03850418 · 43 participants · Phase 2
Azacitidine and Chimerism in MDS or AML Patients After Allogeneic Stem Cell Transplant
- NCT04144023 · 43 participants · Phase 1
A Vaccine (H2NVAC) Before Surgery for the Treatment of HER2-Expressing Ductal Carcinoma In Situ
- NCT04176718 · 43 participants · Phase 2
Daratumumab, Carfilzomib, Pomalidomide, Dexamethasone In MM
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI